As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Pharmaceutical giant Merck (NYSE: MRK) is recognized for its extensive product portfolio of more than 52 drugs covering categories like vaccines, hospital acute care, cardiology, virology ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

Zentalis Pharmaceuticals (ZNTL) announced changes to its executive leadership team to support the Company as it plans and executes ...